The maker of wearable fitness devices has seen its stock sprint higher on the buyout news after languishing this summer near multi-year lows.
These stocks are priced for total imperfection. That's just what you want.
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
Let's review the charts and indicators to see what they are showing today.
M&A activity has generally slowed.
Black-market vaping has made the entire cannabis group toxic.
Both are proud they dodged the Twitter bullet. But, in retrospect, was it really a bullet?
A dividend hike and a big buyback authorization by Mr. Softee should produce value for shareholders.
The cloud stock's results weren't great, but were nothing close to the FedEx disaster.
After a sprint higher in the IT company's shares in recent days, traders and investors might do well to wait for a temporary pullback to pick up the stock.